[CAS NO. 1430114-34-3] BMS-962212
PRODUCTS SPECIFICATIONS [1430114-34-3]
DESCRIPTION [1430114-34-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 659.07 |
| Molecular Formula | C32H28ClFN8O5 |
| SMILES | ClC1=C(F)C(/C=C/C(N2[C@H](C(NC3=CC=C(C(O)=O)C=C3)=O)C(C=CC=C4N5C(CN(C)CC5)=O)=C4CC2)=O)=C(N6C=NN=N6)C=C1 |
Summary
BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor . BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial thromboplastin time, and decreases exposure dependently in FXI clotting activity [1] .
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03197779 | Bristol-Myers Squibb |
Thrombosis
|
November 18, 2013 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 250 mg/mL ( 379.32 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.5173 mL | 7.5864 mL | 15.1729 mL |
| 5 mM | 0.3035 mL | 1.5173 mL | 3.0346 mL |
| 10 mM | 0.1517 mL | 0.7586 mL | 1.5173 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (3.16 mM); Clear solution
